No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?

American Journal of Kidney Diseases

Volumn 68, Issue 3, 2016, Pages 349-352

  Perkins, Bruce A ^a   Udell, Jacob A ^a   Cherney, David Z I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT;

CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG EFFECT; EDITORIAL; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MORTALITY; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK REDUCTION; CARDIOVASCULAR DISEASE; DRUG EFFECTS; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; NATRIURESIS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84962130473     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.03.410     Document Type: Editorial

References (17)

1. 1 Turnbull, F.M., Abraira, C., Anderson, R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:11 (2009), 2288–2298.
2. 2 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:5 (2014), 587–597.
3. 3 Zinman, B., Wanner, C., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:22 (2015), 2117–2128.
4. 4 Inzucchi, S.E., Zinman, B., Wanner, C., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:2 (2015), 90–100.
5. 5 Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis [published online ahead of print May 28, 2014]. Diabetes Obes Metab. http://dx.doi.org/10.1111/dom.12307.
6. 6 Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3:5 (2015), 356–366.
7. 7 Vallon, V., Docherty, N.G., Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp Physiol 99:9 (2014), 1140–1145.
8. 8 White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:14 (2013), 1327–1335.
9. 9 Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:14 (2013), 1317–1326.
10. 10 Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:3 (2015), 232–242.
11. 11 Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:23 (2015), 2247–2257.
12. 12 Vasilakou, D., Karagiannis, T., Athanasiadou, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159:4 (2013), 262–274.
13. 13 Dziuba, J., Alperin, P., Racketa, J., et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 16:7 (2014), 628–635.
14. 14 Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:9 (2013), 853–862.
15. 15 Sha, S., Polidori, D., Farrell, K., et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab 17:2 (2015), 188–197.
16. 16 Rajasekeran, H., Lytvyn, Y., Cherney, D.Z.I., Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 89:3 (2016), 524–526.
17. 17 Skrtic, M., Cherney, D.Z., Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24:1 (2015), 96–103.